

Copenhagen, DK, August 29, 2023

ESGO Council Elections 2024

I am an onco-gynecologist with more than 25 years of experience. I chair the Danish ovarian cancer working group under the Danish Gynecological Cancer Group (DMCG group) and have participated in the preparation of the national guidelines. Through my work in and as a member of the Nordic Society of Gynecological Oncology, I have an international network in the Nordics and the rest of Europe with experience for congress events, education, exchange and research.

I have been the Nordic PI on several international multicenter surgical studies on ovarian cancer; EORTC 99571, DESKTOP III, TRUST and most recently OHVIPEC-2. I am also the national manager for participation in the first project of The ESGO European Database; "Validation of the ESGO Quality Indicators in Advanced Ovarian Cancer Surgery".

Since gynecological cancers are rare, I see the collaboration among the European countries in ESGO as a great strength both in relation to guidelines and research. As a member of the ESGO Council, I would like to contribute to strengthen and further develop this work, and participate in future activities and projects, including further development of ESGO databases.

In the hope of being considered

Kindest regards



Berit Jul Mosgaard
Consultant, MD, PhD
Gyne-Oncology
Department of Gynecology
Copenhagen University Hospital Rigshospitalet
Blegdamsvej 9
2100 København Ø
Telephone: +45 35457940
E-mail: berit.jul.mosgaard.01@regionh.dk

Curriculum vitae

Berit Jul Mosgaard, born December 8., 1962

M.D., Ph.D., gynecologist and senior consultant of the Department of Gynaecology at Rigshospitalet

Education:

1989 Candidate of Medicine from University of Copenhagen

1991 Full registration as Physician

1997 Ph.D. degree - An epidemiological study of Infertility, fertility drugs and risk of ovarian cancer

2000 Specialist in Gynaecology and Obstetrics

2004 Expert in Gynaecologic Oncology (3 years subspecialisation education)

Authorization for medical practice in Sweden 2003 and Norway 2006

Employments

Twenty five years, and since 2004 Consultant, in Gynecology and Obstetrics

2003 Kvinnokliniken, TUMÖR-teamet, Lund, Sweden

2007 Dept Gynaecology, Katholieke University Hospital, Leuven, Belgium

Since 2011 Medical Consultant. Patienterstatningen, Copenhagen

2013-2016 Medical Consultant. SOS International

Honorary offices

Board member Danish Society of Obstetrics and Gynaecology (DSOG) 2007- 2009

Board member DGCG (Danish Gynaecological Cancer Group) since 2009

Advisory Board, Roche, Patientbehov i behandlingsforløb c. ovarii.

Chair (since 2012) of the national Ovarian Cancer Guideline Group (DMCG)

Research

Nordic Study Coordinator (Principal investigator): OVHIPEC-2 A prospective randomized multicentre randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy. NCT03772028

Nordic Study Coordinator (Principal investigator): TRUST A prospective randomized multicentre study on primary radical surgery vs. interval debulking surgery in advanced ovarian carcinoma AGO-OVAR OP.7 NCT02828618

National Study Coordinator (Principal investigator): DESKTOP III A randomised multicentre study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer. AGO-OVAR OP.4 NCT01166737

National Study Coordinator (Principal investigator): EORTC 55971. Randomised phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma.

Principal investigator: Intensification of the treatment of ovarian cancer. MTV.

Co-investigator Delegate for Dansk Gynecologic Cancer Gruppe (DGCG) in **International Cancer Benchmarking Partnership (ICBP)**. The Department of Health in England.

Principal investigator: Quantitative vascular endothelial growth factor (VEGF) in patients with cervical intraepithelial neoplasia and cervical cancer.

Principal investigator: Endometrial cancer, lymphadenectomy and sentinel node.

Co-investigator: Serum levels and tissue expression of YKL-40 and IL-6 in patients with head and neck cancer, cervical cancer and breast cancer.

Co-investigator: Characterization of endometrial cancer with diffusion-weighted MR imaging.

Received Funding

Danish Cancer Society, Rising Tide Foundation, Forsker Akademiet, NovoCare, Lægeforeningens forskningsfond, Minister Erna Hamiltons legat for Videnskab og Kunst, Højmosegaard Legatet, Max og Anna Friedmanns Legat, Toyota Foundation, Løvens Kemiske Fabriks Forskningsfond, Stud med Karsten Hansens mindelegat, Fabrikant Einar Willumsens Mindelegat, Forskningsfonden samarbejde OUH og RH, Neye Fonden

National Guideline Authorships

Ovarian tumours (Danish Society of Obstetrics and Gynaecology (DSOG))

Cervical dysplasia (Danish Society of Obstetrics and Gynaecology (DSOG))

Ovarian Cancer (Danish Gynaecological Cancer Group (DGCG))

Lectures

Since 1993 given more than 60 lectures in national and international congresses, symposiums, and scientific meetings.

Congress and courses

Participated in more than 100 theoretical and practical courses and 100 national and international congresses and scientific meetings.

Member of the Local Organizing Committee, 9th Congress of the European Society of Gynecology, Copenhagen 2011

Lesions

Since 2001 given education to medical students, University of Copenhagen. Examination of student graduating in medicine.

2009-13 Associate professor, University of Copenhagen

Academic advisor and assessment committee of five national and international PhD's.

Other relevant activities

Member of Surgical group in NSGO (Nordic Society of Gynaecological Oncology), especially working on subspecialty training in the Nordic Countries.

Member of the working group in The Danish National Board of Health for preparation of the National integrated cancer pathways for ovarian cancer.

Publication list

AUTHOR: (mosgaard bj) OR AUTHOR: (mosgaard b)

Timespan=1900-2021,

Results found: 59. Ph.D. thesis. Peer-reviewed publications: 44, Reviews: 3, Meeting abstracts: 12,

Sum of the Times Cited: 3369

Average Citations per Item: 57.10

h-index: 20

10 post important publications:

1. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Gregg S, **Mosgaard BJ**, Selle F, et al, du Bois A, DESKTOP III Investigators. *Engl J Med* 2021 Dec 2;385(23):2123-2131
2. **Mosgaard BJ**, Meaidi A, Høgdall C, Noer MC. Risk factors for early death among ovarian cancer patients: a nationwide cohort study. *J Gynecol Oncol*. 2020 May;31(3)
3. Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, **Mosgaard BJ**, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. nt I Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. *J Gynecol Cancer*. 2020 Mar 23
4. Mueller JJ, Lajer H, **Mosgaard BJ**, Bach Hamba S, Morice P, Gouy S, Hussein Y, Soslow RA, Schlappé BA, Zhou QC, Iasonos A, Høgdall C, Leary A, O'Cearbhaill RE, Abu-Rustum NR. International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. *Int J Gynecol Cancer*. 2018 Jun;28(5):915-924
5. Rosendahl M, Høgdall CK, **Mosgaard BJ**. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. *Int J Gynecol Cancer*. 2016 May;26(4):680-7
6. Salvo G, Ramirez PT, Leitao M, Cibula D, Fotopoulou C, Kucukmetin A, Rendon G, Perrotta M, Ribeiro R, Vieira M, Baiocchi G, Falconer H, Persson J, Wu X, Căpilna ME, Ioanid N, **Mosgaard BJ**, Berlev I, Kaidarova D, Olawaiye AB, Liu K, Nobre SP, Kocian R, Saso S, Rundle S, Noll F, Tsunoda AT, Palsdottir K, Li X, Ulrich E, Hu Z, Pareja R. International radical trachelectomy assessment: IRTA study. *Int J Gynecol Cancer*. 2019 Mar;29(3):635-638
7. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, **Mosgaard BJ**, Nordin A, Rosen B, Engholm G, Gjerstorff ML, Hatcher J, Johannesen TB, McGahan CE, Meechan D, Middleton R, Tracey E, Turner D, Richards MA, Rachev B; ICBP Module 1 Working Group. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership *Gynecol Oncol*. 2012 Oct;127(1):75-82
8. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, **Mosgaard BJ**, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer *N Engl J Med*. 2010 Sep 2;363(10):943-53
9. **Mosgaard BJ**, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. *Fertil Steril*. 1997 Jun;67(6):1005-12
10. **Mosgaard BJ**, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Ovarian stimulation and borderline ovarian tumors: a case-control study. *Fertil Steril*. 1998 Dec;70(6):1049-55

Reviewer

Lancet, Human Reproduction, International Journal of Gynaecological Cancer, Danish Medical Bulletin.